Peptides for treatment and prevention of hyperglycaemia
The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.
1. A peptide that induces insulin-independent adipocyte glucose transport wherein
the peptide has a length of at least 15 amino acids and less than 40 amino acids; and
wherein the peptide sequence comprises a sequence selected from the group consisting of:
(SEQ ID NO: 9)
VECTMVEKRVLALLDKPPFLTQLHS;
(SEC) ID NO: 21)
H-VECTM-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
(SEQ ID NO: 22)
H-VECTM-R8-EKRVLA-S5-LDKPPFLTQLHS-NH 2 ;
(SEQ ID NO: 23)
H-CTM-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
(SEQ ID NO: 24)
H-M-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
(SEQ ID NO: 25)
Cbz-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
(SEQ ID NO: 26)
H-VECTM-R8-EKRVLA-S5-LDKPPFLTQL-OH;
(SEQ ID NO: 27)
H-VECTM-R8-EKRVLA-S5-LDKPPFLT-OH;
(SEQ ID NO: 28)
H-VECTM-R8-EKRVLA-S5-LDKPPF-OH;
(SEQ ID NO: 29)
H-VECTM-R8-EKRVLA-S5-LDKP-OH;
(SEQ ID NO: 30)
H-VECTM-R8-EKRVLA-S5-LD-OH;
(SEQ ID NO: 31)
H-VE(AAB)TM-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
and
(SEQ ID NO: 33)
H-VE(AAB)T(AAH)-R8-EKRVLA-S5-LDKPPFLTQLHS-OH.
2. The peptide according to claim 1 , wherein the peptide is modified by a chemical cross-linking process.
3. The peptide according to claim 1 , wherein the peptide sequence consists of:
(SEQ ID NO: 9)
VECTMVEKRVLALLDKPPFLTQLHS;
(SEQ ID NO: 21)
H-VECTM-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
(SEQ ID NO: 22)
H-VECTM-R8-EKRVLA-S5-LDKPPFLTQLHS-NH 2 ;
(SEQ ID NO: 23)
H-CTM-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
(SEQ ID NO: 24)
H-M-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
(SEQ ID NO: 25)
Cbz-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
(SEQ ID NO: 26)
H-VECTM-R8-EKRVLA-S5-LDKPPFLTQL-OH;
(SEQ ID NO: 27)
H-VECTM-R8-EKRVLA-S5-LDKPPFLT-OH;
(SEQ ID NO: 28)
H-VECTM-R8-EKRVLA-S5-LDKPPF-OH;
(SEQ ID NO: 29)
H-VECTM-R8-EKRVLA-S5-LDKP-OH;
(SEQ ID NO: 30)
H-VECTM-R8-EKRVLA-S5-LD-OH;
(SEQ ID NO: 31)
H-VE(AAB)TM-R8-EKRVLA-S5-LDKPPFLTQLHS-OH;
or
(SEQ ID NO: 33)
H-VE(AAB)T(AAH)-R8-EKRVLA-S5-LDKPPFLTQLHS-OH.
4. The peptide according to claim 1 , wherein the peptide has a hydroxyl end group.
5. A pharmaceutical composition comprising a peptide according to claim 1 .
6. The pharmaceutical composition according to claim 5 , said composition further comprising an anti-diabetic agent selected from the group consisting of insulin, metformin, sulfonylurea, alpha-glucosidase inhibitors, thiazolidinediones, meglitinide, incretin mimetic, glucagon-like peptide analog, dipeptidyl peptidase-4 inhibitor, amylin analog, sodium glucose transporter inhibitor, and any combination thereof.